Park looks for strategic partner
Nuclear medicine vendor Park Meditech announced that it will actively seek a strategic partner to assist the company in maximizing its technology within the nuclear medicine market.The announcement came with the release of financial results for the first
Nuclear medicine vendor Park Meditech announced that it will actively seek a strategic partner to assist the company in maximizing its technology within the nuclear medicine market.
The announcement came with the release of financial results for the first six months of 1997 (end-January), which saw the vendor report increased revenues but also a slight increase in its net loss.
For the six-month period, revenues were $4.6 million (Canadian), compared with $3.2 million (Canadian) for the same period in 1996. The company posted a net loss of $5 million (Canadian), compared with $4.9 million in 1996.
The company also reported that the operational reorganization begun in February has mostly been completed (SCAN 3/5/97). In addition, the vendor is shipping its scheduled backlog and is continuing to move ahead in the development of new products, according to Richard Mullen, president and CEO.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
